Professor and consultant of clinical pharmacotherapy for infectious diseases Dirar Balawi Thursday said that the advantage of the Johnson & Johnson COVID-19 vaccine is that it is given in a single dose.
It is yet to be proven that a single dose of the vaccine protects people from coronavirus, he added.
Balawi pointed out that the Sinopharm vaccine is a traditional type vaccine, as the technology differs from that used to manufacture the Johnson & Johnson and Pfizer vaccines. Individuals that got coronavirus can get any of the available vaccines 90 days after recovery.
The senior advisor for the American vaccination program Monsef al-Salawi said the vaccine developed by Johnson & Johnson would be approved in the first half of February.
Salawi described the new vaccine as ‘a game-changer in the United States’, noting that it is in the final phase of trials.